Alanyl-glutamine supplementation for Clostridioides difficile infection treatment (ACT): a double-blind randomised controlled trial study protocol. 2023

Cirle A Warren, and Jae Hyun Shin, and Ekta N Bansal, and Deiziane V D S Costa, and Xin Qun Wang, and Martin Wu, and Jonathan R Swann, and Brian W Behm, and Paul V Targonski, and Laurie Archbald-Pannone
Department of Medicine, Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville, Virginia, USA ca6t@virginia.edu.

Clostridioides difficile is the leading cause of healthcare-associated infections in the USA, with an estimated 1 billion dollars in excess cost to the healthcare system annually. C. difficile infection (CDI) has high recurrence rate, up to 25% after first episode and up to 60% for succeeding episodes. Preliminary in vitro and in vivo studies indicate that alanyl-glutamine (AQ) may be beneficial in treating CDI by its effect on restoring intestinal integrity in the epithelial barrier, ameliorating inflammation and decreasing relapse. This study is a randomised, placebo-controlled, double-blind, phase II clinical trial. The trial is designed to determine optimal dose and safety of oral AQ at 4, 24 and 44 g doses administered daily for 10 days concurrent with standard treatment of non-severe or severe uncomplicated CDI in persons age 18 and older. The primary outcome of interest is CDI recurrence during 60 days post-treatment follow-up, with the secondary outcome of mortality during 60 days post-treatment follow-up. Exploratory analysis will be done to determine the impact of AQ supplementation on intestinal and systemic inflammation, as well as intestinal microbial and metabolic profiles. The study has received University of Virginia Institutional Review Board approval (HSR200046, Protocol v9, April 2023). Findings will be disseminated via conference presentations, lectures and peer-reviewed publications. NCT04305769.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D003015 Clostridium Infections Infections with bacteria of the genus CLOSTRIDIUM and closely related CLOSTRIDIOIDES species. Clostridioides Infections,Clostridioides difficile Infection,Clostridioides perfringens Food Poisoning,Clostridioides perfringens Infections,Clostridioides sordellii Infection,Clostridium difficile Infections,Clostridium sordellii Infections,Clostridium difficile Infection,Clostridium perfringens Food Poisoning,Clostridium perfringens Infections,Clostridium sordellii Infection,Infections, Clostridium,Clostridioides Infection,Clostridioides perfringens Infection,Clostridium Infection,Clostridium perfringens Infection,Infection, Clostridioides difficile,Infection, Clostridioides sordellii,Infection, Clostridium,Infection, Clostridium difficile,Infection, Clostridium sordellii
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D016032 Randomized Controlled Trials as Topic Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Clinical Trials, Randomized,Controlled Clinical Trials, Randomized,Trials, Randomized Clinical
D016360 Clostridioides difficile A common inhabitant of the colon flora in human infants and sometimes in adults. The type species Clostridioides difficile is formerly known as Clostridium difficile. It is a causative agent for CLOSTRIDIOIDES INFECTIONS and is associated with PSEUDOMEMBRANOUS ENTEROCOLITIS in patients receiving antibiotic therapy. Clostridium difficile
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Cirle A Warren, and Jae Hyun Shin, and Ekta N Bansal, and Deiziane V D S Costa, and Xin Qun Wang, and Martin Wu, and Jonathan R Swann, and Brian W Behm, and Paul V Targonski, and Laurie Archbald-Pannone
December 2022, The lancet. Gastroenterology & hepatology,
Cirle A Warren, and Jae Hyun Shin, and Ekta N Bansal, and Deiziane V D S Costa, and Xin Qun Wang, and Martin Wu, and Jonathan R Swann, and Brian W Behm, and Paul V Targonski, and Laurie Archbald-Pannone
July 1999, Gut,
Cirle A Warren, and Jae Hyun Shin, and Ekta N Bansal, and Deiziane V D S Costa, and Xin Qun Wang, and Martin Wu, and Jonathan R Swann, and Brian W Behm, and Paul V Targonski, and Laurie Archbald-Pannone
September 2015, Contemporary clinical trials,
Cirle A Warren, and Jae Hyun Shin, and Ekta N Bansal, and Deiziane V D S Costa, and Xin Qun Wang, and Martin Wu, and Jonathan R Swann, and Brian W Behm, and Paul V Targonski, and Laurie Archbald-Pannone
June 2023, Journal of the Pediatric Infectious Diseases Society,
Cirle A Warren, and Jae Hyun Shin, and Ekta N Bansal, and Deiziane V D S Costa, and Xin Qun Wang, and Martin Wu, and Jonathan R Swann, and Brian W Behm, and Paul V Targonski, and Laurie Archbald-Pannone
May 2024, BMJ open,
Cirle A Warren, and Jae Hyun Shin, and Ekta N Bansal, and Deiziane V D S Costa, and Xin Qun Wang, and Martin Wu, and Jonathan R Swann, and Brian W Behm, and Paul V Targonski, and Laurie Archbald-Pannone
September 1989, BMJ (Clinical research ed.),
Cirle A Warren, and Jae Hyun Shin, and Ekta N Bansal, and Deiziane V D S Costa, and Xin Qun Wang, and Martin Wu, and Jonathan R Swann, and Brian W Behm, and Paul V Targonski, and Laurie Archbald-Pannone
September 1996, Acta obstetricia et gynecologica Scandinavica,
Cirle A Warren, and Jae Hyun Shin, and Ekta N Bansal, and Deiziane V D S Costa, and Xin Qun Wang, and Martin Wu, and Jonathan R Swann, and Brian W Behm, and Paul V Targonski, and Laurie Archbald-Pannone
May 2023, The Journal of international medical research,
Cirle A Warren, and Jae Hyun Shin, and Ekta N Bansal, and Deiziane V D S Costa, and Xin Qun Wang, and Martin Wu, and Jonathan R Swann, and Brian W Behm, and Paul V Targonski, and Laurie Archbald-Pannone
August 2019, BMJ open,
Cirle A Warren, and Jae Hyun Shin, and Ekta N Bansal, and Deiziane V D S Costa, and Xin Qun Wang, and Martin Wu, and Jonathan R Swann, and Brian W Behm, and Paul V Targonski, and Laurie Archbald-Pannone
March 2016, BMJ open,
Copied contents to your clipboard!